Skip to main content Accessibility help

Cognitive effects of adjunctive N-acetyl cysteine in psychosis

  • M. Rapado-Castro (a1) (a2) (a3), S. Dodd (a4) (a5), A. I. Bush (a5), G. S. Malhi (a6) (a7) (a8), D. R. Skvarc (a4), Z. X. On (a9), M. Berk (a3) (a4) (a5) (a10) and O. M. Dean (a4) (a5) (a10)...



Cognitive deficits are predictors of functional outcome in patients with psychosis. While conventional antipsychotics are relatively effective on positive symptoms, their impact on negative and cognitive symptoms is limited. Recent studies have established a link between oxidative stress and neurocognitive deficits in psychosis. N-acetylcysteine (NAC), a glutathione precursor with glutamatergic properties, has shown efficacy on negative symptoms and functioning in patients with schizophrenia and bipolar disorder, respectively. However, there are few evidence-based approaches for managing cognitive impairment in psychosis. The present study aims to examine the cognitive effects of adjunctive NAC treatment in a pooled subgroup of participants with psychosis who completed neuropsychological assessment in two trials of both schizophrenia and bipolar disorder.


A sample of 58 participants were randomized in a double fashion to receive 2 g/day of NAC (n = 27) or placebo (n = 31) for 24 weeks. Attention, working memory and executive function domains were assessed. Differences between cognitive performance at baseline and end point were examined using Wilcoxon's test. The Mann–Whitney test was used to examine the differences between the NAC and placebo groups at the end point.


Participants treated with NAC had significantly higher working memory performance at week 24 compared with placebo (U = 98.5, p = 0.027).


NAC may have an impact on cognitive performance in psychosis, as a significant improvement in working memory was observed in the NAC-treated group compared with placebo; however, these preliminary data require replication. Glutamatergic compounds such as NAC may constitute a step towards the development of useful therapies for cognitive impairment in psychosis.


Corresponding author

*Address for correspondence: M. Berk, Deakin University, PO Box 281, Geelong, VIC 3220, Australia. (Email:


Hide All
† Equally contributing authors.



Hide All
Adair, JC, Knoefel, JE, Morgan, N (2001). Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 57, 15151517.
Amen, DG, Taylor, DV, Ojala, K, Kaur, J, Willeumier, K (2013). Effects of brain-directed nutrients on cerebral blood flow and neuropsychological testing: a randomized, double-blind, placebo-controlled, crossover trial. Advances in Mind–Body Medicine 27, 2433.
Amen, DG, Wu, JC, Taylor, D, Willeumier, K (2011). Reversing brain damage in former NFL players: implications for traumatic brain injury and substance abuse rehabilitation. Journal of Psychoactive Drugs 43, 15.
Arango, C, Fraguas, D, Parellada, M (2014). Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders. Schizophrenia Bulletin 40 (Suppl. 2), S138S146.
Bang, M, Kim, KR, Song, YY, Baek, S, Lee, E, An, SK (2015). Neurocognitive impairments in individuals at ultra-high risk for psychosis: who will really convert? Australian and New Zealand Journal of Psychiatry 49, 462470.
Banks, PJ, Warburton, EC, Brown, MW, Bashir, ZI (2014). Mechanisms of synaptic plasticity and recognition memory in the perirhinal cortex. Progress in Molecular Biology and Translational Science 122, 193209.
Bauer, IE, Pascoe, MC, Wollenhaupt-Aguiar, B, Kapczinski, F, Soares, JC (2014). Inflammatory mediators of cognitive impairment in bipolar disorder. Journal of Psychiatric Research 56, 1827.
Berk, M, Copolov, D, Dean, O, Lu, K, Jeavons, S, Schapkaitz, I, Anderson-Hunt, M, Judd, F, Katz, F, Katz, P, Ording-Jespersen, S, Little, J, Conus, P, Cuenod, M, Do, KQ, Bush, AI (2008 a). N-acetyl cysteine as a glutathione precursor for schizophrenia – a double-blind, randomized, placebo-controlled trial. Biological Psychiatry 64, 361368.
Berk, M, Copolov, DL, Dean, O, Lu, K, Jeavons, S, Schapkaitz, I, Anderson-Hunt, M, Bush, AI (2008 b). N-acetyl cysteine for depressive symptoms in bipolar disorder – a double-blind randomized placebo-controlled trial. Biological Psychiatry 64, 468475.
Berk, M, Malhi, GS, Gray, LJ, Dean, OM (2013). The promise of N-acetylcysteine in neuropsychiatry. Trends in Pharmacological Sciences 34, 167177.
Berk, M, Munib, A, Dean, O, Malhi, GS, Kohlmann, K, Schapkaitz, I, Jeavons, S, Katz, F, Anderson-Hunt, M, Conus, P, Hanna, B, Otmar, R, Ng, F, Copolov, DL, Bush, AI (2011). Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia. Journal of Clinical Psychiatry 72, 909913.
Berk, M, Ng, F, Dean, O, Dodd, S, Bush, AI (2008 c). Glutathione: a novel treatment target in psychiatry. Trends in Pharmacological Sciences 29, 346351.
Bombin, I, Mayoral, M, Castro-Fornieles, J, Gonzalez-Pinto, A, de la Serna, E, Rapado-Castro, M, Barbeito, S, Parellada, M, Baeza, I, Graell, M, Paya, B, Arango, C (2013). Neuropsychological evidence for abnormal neurodevelopment associated with early-onset psychoses. Psychological Medicine 43, 757768.
Bora, E, Pantelis, C (2015). Meta-analysis of cognitive impairment in first-episode bipolar disorder: comparison with first-episode schizophrenia and healthy controls. Schizophrenia Bulletin 41, 10951104.
Bora, E, Yucel, M, Pantelis, C (2009). Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study. British Journal of Psychiatry 195, 475482.
Bulut, M, Savas, HA, Altindag, A, Virit, O, Dalkilic, A (2009). Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. World Journal of Biological Psychiatry 10, 626628.
Carmeli, C, Knyazeva, MG, Cuenod, M, Do, KQ (2012). Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial. PLOS ONE 7, e29341.
Chan, A, Paskavitz, J, Remington, R, Rasmussen, S, Shea, TB (2008). Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension. American Journal of Alzheimer's Disease and Other Dementias 23, 571585.
Chan, A, Remington, R, Kotyla, E, Lepore, A, Zemianek, J, Shea, TB (2010). A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia. Journal of Nutrition, Health and Aging 14, 224230.
Choy, KH, Dean, O, Berk, M, Bush, AI, van den Buuse, M (2010). Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats. European Journal of Pharmacology 649, 224228.
Daban, C, Martinez-Aran, A, Torrent, C, Tabares-Seisdedos, R, Balanza-Martinez, V, Salazar-Fraile, J, Selva-Vera, G, Vieta, E (2006). Specificity of cognitive deficits in bipolar disorder versus schizophrenia. A systematic review. Psychotherapy and Psychosomatics 75, 7284.
Daglas, R, Yucel, M, Cotton, S, Allott, K, Hetrick, S, Berk, M (2015). Cognitive impairment in first-episode mania: a systematic review of the evidence in the acute and remission phases of the illness. International Journal of Bipolar Disorders 3, 9.
Davis, J, Moylan, S, Harvey, BH, Maes, M, Berk, M (2014). Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries. Australian and New Zealand Journal of Psychiatry 48, 512529.
Dean, O, Giorlando, F, Berk, M (2011). N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. Journal of Psychiatry and Neuroscience 36, 7886.
Dean, OM, Bush, AI, Copolov, DL, Kohlmann, K, Jeavons, S, Schapkaitz, I, Anderson-Hunt, M, Berk, M (2012). Effects of N-acetyl cysteine on cognitive function in bipolar disorder. Psychiatry and Clinical Neurosciences 66, 514517.
Debnath, M, Venkatasubramanian, G, Berk, M (2015). Fetal programming of schizophrenia: select mechanisms. Neuroscience and Biobehavioral Reviews 49, 90104.
Deepmala, , Slattery, J, Kumar, N, Delhey, L, Berk, M, Dean, O, Spielholz, C, Frye, R (2015). Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neuroscience and Biobehavioral Reviews 55, 294321.
Dodd, S, Maes, M, Anderson, G, Dean, OM, Moylan, S, Berk, M (2013). Putative neuroprotective agents in neuropsychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 42, 135145.
Driesen, NR, McCarthy, G, Bhagwagar, Z, Bloch, MH, Calhoun, VD, D'Souza, DC, Gueorguieva, R, He, G, Leung, HC, Ramani, R, Anticevic, A, Suckow, RF, Morgan, PT, Krystal, JH (2013). The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. Neuropsychopharmacology 38, 26132622.
Fett, AK, Viechtbauer, W, Dominguez, MD, Penn, DL, van Os, J, Krabbendam, L (2011). The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neuroscience and Biobehavioral Reviews 35, 573588.
Frydecka, D, Eissa, AM, Hewedi, DH, Ali, M, Drapala, J, Misiak, B, Klosinska, E, Phillips, JR, Moustafa, AA (2014). Impairments of working memory in schizophrenia and bipolar disorder: the effect of history of psychotic symptoms and different aspects of cognitive task demands. Frontiers in Behavioral Neuroscience 8, 416.
Fusar-Poli, P, Deste, G, Smieskova, R, Barlati, S, Yung, AR, Howes, O, Stieglitz, RD, Vita, A, McGuire, P, Borgwardt, S (2012). Cognitive functioning in prodromal psychosis: a meta-analysis. Archives of General Psychiatry 69, 562571.
Fusar-Poli, P, Stone, JM, Broome, MR, Valli, I, Mechelli, A, McLean, MA, Lythgoe, DJ, O'Gorman, RL, Barker, GJ, McGuire, PK (2011). Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Archives of General Psychiatry 68, 881890.
Gelman, A, Hill, J, Yajima, M (2009). Why we (usually) don't have to worry about multiple comparisons (
Goldman, HH, Skodol, AE, Lave, TR (1992). Revising Axis V for DSM-IV: a review of measures of social functioning. American Journal of Psychiatry 149, 11481156.
Gonzalez-Ortega, I, de Los Mozos, V, Echeburua, E, Mezo, M, Besga, A, Ruiz de Azua, S, Gonzalez-Pinto, A, Gutierrez, M, Zorrilla, I, Gonzalez-Pinto, A (2013). Working memory as a predictor of negative symptoms and functional outcome in first episode psychosis. Psychiatry Research 206, 816.
Gray, JA, Roth, BL (2007). Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophrenia Bulletin 33, 11001119.
Gunduz-Bruce, H (2009). The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Research Reviews 60, 279286.
Gunduz-Bruce, H, Reinhart, RM, Roach, BJ, Gueorguieva, R, Oliver, S, D'Souza, DC, Ford, JM, Krystal, JH, Mathalon, DH (2012). Glutamatergic modulation of auditory information processing in the human brain. Biological Psychiatry 71, 969–977.
Hall, RC (1995). Global assessment of functioning. A modified scale. Psychosomatics 36, 267275.
Hanson, DR, Gottesman, II (2005). Theories of schizophrenia: a genetic–inflammatory–vascular synthesis. BMC Medical Genetics 6, 7.
Heinrichs, RW, Zakzanis, KK (1998). Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12, 426445.
Hill, SK, Reilly, JL, Keefe, RS, Gold, JM, Bishop, JR, Gershon, ES, Tamminga, CA, Pearlson, GD, Keshavan, MS, Sweeney, JA (2013). Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. American Journal of Psychiatry 170, 12751284.
Hoffer, ME, Balaban, C, Slade, MD, Tsao, JW, Hoffer, B (2013). Amelioration of acute sequelae of blast induced mild traumatic brain injury by N-acetyl cysteine: a double-blind, placebo controlled study. PLOS ONE 8, e54163.
Hoffman, RE, Woods, SW, Hawkins, KA, Pittman, B, Tohen, M, Preda, A, Breier, A, Glist, J, Addington, J, Perkins, DO, McGlashan, TH (2007). Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population. British Journal of Psychiatry 191, 355356.
Holmay, MJ, Terpstra, M, Coles, LD, Mishra, U, Ahlskog, M, Oz, G, Cloyd, JC, Tuite, PJ (2013). N-acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clinical Neuropharmacology 36, 103106.
Howes, O, McCutcheon, R, Stone, J (2015). Glutamate and dopamine in schizophrenia: an update for the 21st century. Journal of Psychopharmacology 29, 97115.
Javitt, DC, Zukin, SR, Heresco-Levy, U, Umbricht, D (2012). Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophrenia Bulletin 38, 958966.
Jayalakshmi, K, Singh, SB, Kalpana, B, Sairam, M, Muthuraju, S, Ilavazhagan, G (2007). N-acetyl cysteine supplementation prevents impairment of spatial working memory functions in rats following exposure to hypobaric hypoxia. Physiology and Behavior 92, 643650.
Kahn, RS, Sommer, IE (2015). The neurobiology and treatment of first-episode schizophrenia. Molecular Psychiatry 20, 8497.
Kantrowitz, JT, Javitt, DC (2010). N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Research Bulletin 83, 108121.
Kapur, S (2003). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry 160, 1323.
Kay, SR, Fiszbein, A, Opler, LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261276.
Kim, D, Kim, JW, Koo, TH, Yun, HR, Won, SH (2015). Shared and distinct neurocognitive endophenotypes of schizophrenia and psychotic bipolar disorder. Clinical Psychopharmacology and Neuroscience 13, 94102.
Kozicky, JM, Torres, IJ, Silveira, LE, Bond, DJ, Lam, RW, Yatham, LN (2014). Cognitive change in the year after a first manic episode: association between clinical outcome and cognitive performance early in the course of bipolar I disorder. Journal of Clinical Psychiatry 75, e587e593.
Krabbendam, L, Arts, B, van Os, J, Aleman, A (2005). Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. Schizophrenia Research 80, 137149.
Lavoie, S, Murray, MM, Deppen, P, Knyazeva, MG, Berk, M, Boulat, O, Bovet, P, Bush, AI, Conus, P, Copolov, D, Fornari, E, Meuli, R, Solida, A, Vianin, P, Cuenod, M, Buclin, T, Do, KQ (2008). Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 33, 21872199.
Lopez-Jaramillo, C, Lopera-Vasquez, J, Gallo, A, Ospina-Duque, J, Bell, V, Torrent, C, Martinez-Aran, A, Vieta, E (2010). Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disorders 12, 557567.
Malhi, GS, Ivanovski, B, Hadzi-Pavlovic, D, Mitchell, PB, Vieta, E, Sachdev, P (2007). Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disorders 9, 114125.
Martinez-Aran, A, Penades, R, Vieta, E, Colom, F, Reinares, M, Benabarre, A, Salamero, M, Gasto, C (2002). Executive function in patients with remitted bipolar disorder and schizophrenia and its relationship with functional outcome. Psychotherapy and Psychosomatics 71, 3946.
Martinez-Aran, A, Vieta, E (2015). Cognition as a target in schizophrenia, bipolar disorder and depression. European Neuropsychopharmacology 25, 151157.
Martinez-Cengotitabengoa, M, Mac-Dowell, KS, Leza, JC, Mico, JA, Fernandez, M, Echevarria, E, Sanjuan, J, Elorza, J, Gonzalez-Pinto, A (2012). Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophrenia Research 137, 6672.
Martinez-Cengotitabengoa, M, Mico, JA, Arango, C, Castro-Fornieles, J, Graell, M, Paya, B, Leza, JC, Zorrilla, I, Parellada, M, Lopez, MP, Baeza, I, Moreno, C, Rapado-Castro, M, Gonzalez-Pinto, A (2014). Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study. Schizophrenia Research 156, 2329.
Mesholam-Gately, RI, Giuliano, AJ, Goff, KP, Faraone, SV, Seidman, LJ (2009). Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 23, 315336.
Millan, MJ, Agid, Y, Brune, M, Bullmore, ET, Carter, CS, Clayton, NS, Connor, R, Davis, S, Deakin, B, DeRubeis, RJ, Dubois, B, Geyer, MA, Goodwin, GM, Gorwood, P, Jay, TM, Joëls, M, Mansuy, IM, Meyer-Lindenberg, A, Murphy, D, Rolls, E, Saletu, B, Spedding, M, Sweeney, J, Whittington, M, Young, LJ (2012). Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature Reviews. Drug Discovery 11, 141168.
Miskowiak, KW, Ehrenreich, H, Christensen, EM, Kessing, LV, Vinberg, M (2014). Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. Journal of Clinical Psychiatry 75, 13471355.
Morgan, CJ, Mofeez, A, Brandner, B, Bromley, L, Curran, HV (2004). Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 29, 208218.
Morris, G, Berk, M (2015). The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Medicine 13, 68.
Ng, F, Berk, M, Dean, O, Bush, AI (2008). Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. International Journal of Neuropsychopharmacology 11, 851876.
Otte, DM, Sommersberg, B, Kudin, A, Guerrero, C, Albayram, O, Filiou, MD, Frisch, P, Yilmaz, O, Drews, E, Turck, CW, Bilkei-Gorzo, A, Kunz, WS, Beck, H, Zimmer, A (2011). N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice. Neuropsychopharmacology 36, 22332243.
Pantelis, C, Wannan, C, Bartholomeusz, CF, Allott, K, McGorry, PD (2015). Cognitive intervention in early psychosis – preserving abilities versus remediating deficits. Current Opinion in Behavioral Sciences 4, 6372.
Potvin, S, Pampoulova, T, Lipp, O, Ait Bentaleb, L, Lalonde, P, Stip, E (2008). Working memory and depressive symptoms in patients with schizophrenia and substance use disorders. Cognitive Neuropsychiatry 13, 357366.
Rajasekaran, A, Venkatasubramanian, G, Berk, M, Debnath, M (2015). Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications. Neuroscience and Biobehavioral Reviews 48, 1021.
Rapado-Castro, M, Berk, M, Venugopal, K, Bush, AI, Dodd, S, Dean, OM (2015). Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 57, 6975.
Reichenberg, A, Caspi, A, Harrington, H, Houts, R, Keefe, RS, Murray, RM, Poulton, R, Moffitt, TE (2010). Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. American Journal of Psychiatry 167, 160169.
Reilly, JL, Sweeney, JA (2014). Generalized and specific neurocognitive deficits in psychotic disorders: utility for evaluating pharmacological treatment effects and as intermediate phenotypes for gene discovery. Schizophrenia Bulletin 40, 516522.
Reus, GZ, Fries, GR, Stertz, L, Badawy, M, Passos, IC, Barichello, T, Kapczinski, F, Quevedo, J (2015). The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 300, 141154.
Riedel, G, Platt, B, Micheau, J (2003). Glutamate receptor function in learning and memory. Behavioural Brain Research 140, 147.
Rosa, AR, Magalhães, PV, Czepielewski, L, Sulzbach, MV, Goi, PD, Vieta, E, Gama, CS, Kapczinski, F (2014). Clinical staging in bipolar disorder: focus on cognition and functioning. Journal of Clinical Psychiatry 75, e450e456.
Saetre, P, Emilsson, L, Axelsson, E, Kreuger, J, Lindholm, E, Jazin, E (2007). Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 7, 46.
Samuni, Y, Goldstein, S, Dean, OM, Berk, M (2013). The chemistry and biological activities of N-acetylcysteine. Biochimica et Biophysica Acta 1830, 41174129.
Shaikh, M, Valmaggia, L, Broome, MR, Dutt, A, Lappin, J, Day, F, Woolley, J, Tabraham, P, Walshe, M, Johns, L, Fusar-Poli, P, Howes, O, Murray, RM, McGuire, P, Bramon, E (2012). Reduced mismatch negativity predates the onset of psychosis. Schizophrenia Research 134, 4248.
Shungu, DC (2012). N-acetylcysteine for the treatment of glutathione deficiency and oxidative stress in schizophrenia. Biological Psychiatry 71, 937938.
Stone, JM, Bramon, E, Pauls, A, Sumich, A, McGuire, PK (2010). Thalamic neurochemical abnormalities in individuals with prodromal symptoms of schizophrenia – relationship to auditory event-related potentials. Psychiatry Research 183, 174176.
van Os, J, Kapur, S (2009). Schizophrenia. Lancet 374, 635645.
Vreeker, A, van Bergen, AH, Kahn, RS (2015). Cognitive enhancing agents in schizophrenia and bipolar disorder. European Neuropsychopharmacology 25, 9691002.
Williams, JB, Kobak, KA (2008). Development and reliability of a Structured Interview Guide for the Montgomery–Åsberg Depression Rating Scale (SIGMA). British Journal of Psychiatry 192, 5258.
Wilson, CJ, Finch, CE, Cohen, HJ (2002). Cytokines and cognition – the case for a head-to-toe inflammatory paradigm. Journal of the American Geriatrics Society 50, 20412056.
Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA (1978). A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 133, 429435.
Zabala, A, Rapado, M, Arango, C, Robles, O, de la Serna, E, Gonzalez, C, Rodriguez-Sanchez, JM, Andres, P, Mayoral, M, Bombin, I (2010). Neuropsychological functioning in early-onset first-episode psychosis: comparison of diagnostic subgroups. European Archives of Psychiatry and Clinical Neuroscience 260, 225233.


Related content

Powered by UNSILO
Type Description Title
Supplementary materials

Rapado-Castro supplementary material
Table S1

 Word (41 KB)
41 KB

Cognitive effects of adjunctive N-acetyl cysteine in psychosis

  • M. Rapado-Castro (a1) (a2) (a3), S. Dodd (a4) (a5), A. I. Bush (a5), G. S. Malhi (a6) (a7) (a8), D. R. Skvarc (a4), Z. X. On (a9), M. Berk (a3) (a4) (a5) (a10) and O. M. Dean (a4) (a5) (a10)...


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.